Skip to content

ESMO Congress 2026

October 23–27, 2026 · Madrid · 3101 items

← Floor

DELLPHI-305

★★★Late-breaking

65 people · 88 posts · 1 abstract

Heat trend for this story

Heat now 36·Peak in the comparable set 41 (Oct 25 02:00)·Change over 24h in the comparable set –·Participants now 56

Participants counted56
0204060
Heat over time
0204060Oct24Oct24Oct25Oct25
Deep dive

Tarlatamab is a bispecific T-cell engager (BiTE) targeting DLL3×CD3 that received US FDA approval for small cell lung cancer (SCLC) in 2024, one of the antibody new molecular entities approved that year, based on phase II data showing improved response rates and progression-free survival over standard of care in previously treated SCLC, with multiple phase III studies following [1][2][6]. SCLC is initially sensitive to platinum chemotherapy but develops resistance rapidly and carries a dismal prognosis, and the benefits of PD-(L)1 inhibitors and ADCs remain limited [4]. CRS is the main safety concern; the DeLLphi-300 substudy showed that with 6–8-hour outpatient monitoring in cycle 1, any-grade CRS was around 60%, comparable to 48-hour inpatient monitoring (62%), supporting feasibility for broader use [5].

The Presidential Symposium LBA3 at ESMO 2026 reported the phase III DeLLphi-305: after induction with first-line chemotherapy plus durvalumab in ES-SCLC, patients were randomized to tarlatamab plus durvalumab versus durvalumab alone as maintenance. Amgen announced on 8 September that the trial met its OS endpoint at an interim analysis; the figures presented were OS 21.1 vs 12.7 months (HR 0.42), PFS 7.4 vs 1.9 months (HR 0.34), CRS incidence 49.6% with grade ≥3 of only 0.4%. The presenter was Jacob Sands, 24 October (Saturday), 17:18, Hall 6.

Relative to prior knowledge, DeLLphi-305 advances tarlatamab's evidence from the previously treated setting [2][5] into first-line maintenance, directly combined with a PD-L1 inhibitor, and the OS HR 0.42 magnitude made it one of the three Presidential Symposium presentations. The live posts also discussed a second thread: an indirect contrast with IMforte (atezolizumab plus lurbinectedin maintenance, OS HR 0.73). The poster explicitly noted that cross-trial comparisons are inappropriate, though tarlatamab's OS benefit appeared numerically much greater; another post claimed tarlatamab enters the brain while the IMforte regimen does not — this reflects the poster's view, with no supporting data presented at the meeting, and remains to be confirmed.

As for limitations, only conference topline figures are available so far; OS maturity, subsequent lines of therapy, CNS efficacy, quality of life and the full safety profile await full publication. The durvalumab monotherapy arm's PFS was only 1.9 months, and whether the combination's benefit is durable requires longer follow-up.

References
  1. 1.Antibodies to watch in 2025 · MAbs 2025
  2. 2.DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy · Mol Cancer 2024
  3. 3.Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities · Signal Transduct Target Ther 2024
  4. 4.Current and future therapies for small cell lung carcinoma · J Hematol Oncol 2025
  5. 5.Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy · ESMO Open 2025
  6. 6.Structure and function of therapeutic antibodies approved by the US FDA in 2024 · Antib Ther 2025
Evidence
LBA3

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org
Floor
  1. Dr Rishabh Jain

    ESMO 2026 | TOP 10 LUNG CANCER TRIALS TO WATCH!

    引用@

    🚨 ESMO 2026: 15 Trials That Could Change Oncology Practice! From personalized cancer vaccines and bispecific antibodies to next-generation ADCs, major results are coming. 🔥 My Top 15 to Watch: 1. INTerpath-001 | Melanoma 2. SAFFRON | EGFR+ NSCLC 3. Krascendo 1 | KRAS G12C NSCLC 4. DeLLphi-305 | ES-SCLC 5. HARMONi-GI1 | Biliary 6. VOLGA | Bladder 7. DASL-HiCaP | Prostate 8. NATALEE | Breast 9. TRIO-US B-12 TALENT | Breast 10. ENERGIZE | Bladder 11. CLARITY-Gastric 01 | Gastric 12. KEYNOTE-C93 | Endometrial 13. KEYNOTE-B49 | Breast 14. LITESPARK-011 | RCC 15. SigVie-002 | NSCLC 📊 The big question: Which trials will deliver meaningful survival benefits and redefine standards of care? Not every positive trial is practice-changing. 👨‍⚕️ Oncologists, which trial are you watching most closely? #ESMO26 #Oncology #CancerResearch @ASCO @oncoalert @myesmo @esmo_open

    ★★★Same topic DELLPHI-305 · 65 peopleSAFFRONKRASCENDODELLPHI-304ASTRIDEtarlatamabdurvalumabosimertinibsavolitinib6934 views88 likes27 reposts0 replies
  21. Dra. María Natalia Gandur Quiroga

    🚨 #ESMO26 Lung Cancer: the 10 studies that best capture where the field is moving

    引用@

    🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁 The abstracts our faculty picked as must-know from Madrid 👇 1️⃣ DeLLphi-305 (LBA3): tarlatamab + durvalumab, 1L maintenance in ES-SCLC 2️⃣ Krascendo 1 (LBA5): divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC 3️⃣ SAFFRON (LBA6): osimertinib + savolitinib in EGFRm MET+ NSCLC post-osimertinib 4️⃣ OptiTROP-Lung04 (LBA67): final OS, sac-TMT vs chemo after EGFR-TKI 5️⃣ OptiTROP-Lung06 (LBA66): sac-TMT + pembro, 1L PD-L1-negative non-squamous NSCLC 6️⃣ PERSEE (2614O): pembro ± chemo, 1L PD-L1 ≥50% 7️⃣ SANOVO (LBA69): savolitinib + osimertinib, 1L EGFRm MET-overexpressed NSCLC 8️⃣ IFCT-2103 DIAL (2618RO): continue pembro vs observation at 6 months 9️⃣ PANKU-Lung01 (LBA71): iza-bren after third-generation EGFR TKI 🔟 SARON (2613O): consolidation radiotherapy in oligometastatic NSCLC #lcsm #OncoAlert #MedTwitter Pinging our OncoAlert Lung Cancer Faculty @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @bensolomon1 @VanitaNoronha +@alexdrilon @JordiRemon @caliraf @JulienMazieres @TerriConneran

    Same topic DELLPHI-305 · 65 peopleKRASCENDOSAFFRONSANOVOtarlatamabdurvalumabdivarasibsotorasibadagrasib407 views4 likes3 reposts0 replies
  25. Masahiro TORASAWA, MD. PhD.

    #ESMO26 LBA3

    引用@

    1/4 🔥 #ESMO26 Lung Cancer Presidential Highlights 🇪🇸 Madrid | October 24–25, 2026 Three major Phase 3 lung cancer LBAs, each with potential to reshape treatment paradigms: 🎙️ LBA3 | DeLLphi-305 🎙️ LBA5 | KRASCENDO 1 🎙️ LBA6 | SAFFRON Three Phase 3 readouts to watch closely at #ESMO26 👀 @myESMO @OncoAlert @Larvol

    Same topic DELLPHI-305 · 65 peopleLBA3tarlatamabdurvalumab335 views6 likes0 reposts1 reply
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org